Previous evidence revealed that EPA activated peroxisome proliferator-activated receptor (PPAR), which mediated the oxidation of FAs in the liver and exhibited a better anti-obesity effect than DHA [72], whereas DHA more effectively induced a browning process and promoted lipid metabolism in white adipose tissue [73], which indicated potential differences between DHA and EPA in regulating metabolic homeostasis. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.